Awareness of HBV Functional Cure and Attitude Toward Related Clinical Trials Among Patients with Chronic Hepatitis B in China
Zhongping Duan,Jinling Dong,Ying Liu,Haiyang Zhou,Shuli Duan,Weihong Liu,Rico Liang,Yue Ding
DOI: https://doi.org/10.2147/PPA.S422916
2023-08-23
Patient Preference and Adherence
Abstract:Zhongping Duan, 1 Jinling Dong, 1 Ying Liu, 2 Haiyang Zhou, 2 Shuli Duan, 2 Weihong Liu, 3 Rico Liang, 3 Yue Ding 3 1 Fourth Department of Hepatology Center, Beijing You'an Hospital, Capital Medical University, Beijing, People's Republic of China; 2 iGandan, the Portal for All Liver Disease Caring, Beijing, People's Republic of China; 3 Brii Biosciences Inc., Beijing, People's Republic of China Correspondence: Rico Liang, Brii Biosciences Inc, 3F, Building 7, Zhongguancun Dongsheng International Science Park, No. 1 North. Yongtaizhuang Road, Haidian District, Beijing, 100192, People's Republic of China, Tel/Fax +86 10 6587 6121, Email Purpose: HBV functional cure is an optimal treatment goal for chronic hepatitis B (CHB) at present and numerous new drugs aiming for HBV functional cure are in development. We carried out an internet-based survey to understand the treatment status, unmet needs, awareness of HBV functional cure and attitude toward related clinical trials among CHB patients in China. Patients and Methods: An internet-based anonymous survey was conducted on CHB patients who reside in mainland China. Determinants of awareness and attitude were identified by logistic regression models. Results: Of the 1220 CHB patients who completed the survey questionnaire, 11.1% (135/1220) were aware of HBV functional cure and 50.2% (612/1220) answered "definitely will" to participate in related clinical trials. Participants who knew their HBsAg level (HBsAg< 1500 IU/mL: OR=3.03, 95% CI: 1.87– 4.92; HBsAg≥ 1500 IU/mL: OR=2.57, 95% CI: 1.35– 4.88), who expected to achieve HBsAg loss with treatment (OR=1.63, 95% CI: 1.07– 2.50) and who were dissatisfied with current treatment due to the failure of achieving HBsAg loss (OR=1.67, 95% CI: 1.10– 2.53) had better awareness of HBV functional cure. Participants who had HBsAg level less than 1500 IU/mL (OR=1.45, 95% CI: 1.05– 1.99), treatment with pegylated interferon alpha with or without nucleos(t)ide (OR=1.68, 95% CI: 1.11– 2.53) and better awareness of HBV functional cure (OR=1.62, 95% CI: 1.01– 2.61) were more likely to say "definitely will" to participate in related clinical trials. Conclusion: Chinese CHB patients reported a low awareness of HBV functional cure. Although CHB patients in China reported a low rate of HBV functional cure awareness, they had a high acceptance of related clinical trials. Keywords: CHB, HBV functional cure, awareness, related clinical trials Hepatitis B virus (HBV) infection is a global public health concern, and patients with HBV infection are at high risk of progressive liver diseases and hepatocellular carcinoma (HCC). China has the largest chronic hepatitis B (CHB) burden with an estimated 7.8% hepatitis B surface antigen (HBsAg) seroprevalence rate and 11.4 per 100,000 all-age death rate for HBV-related diseases in 2019. 1 Increasing levels of HBV DNA, HBsAg, and ALT were associated with an increasing risk of HCC. 2 Studies have reported that HBsAg seroclearance can further reduce HCC risk after complete viral suppression and was associated with improved patient outcomes. 3,4 However, current CHB standard of care (SoC) treatment can only achieve a low rate of HBsAg seroclearance. 5–7 HBV functional cure, defined as sustained, undetectable HBsAg and HBV DNA in serum with or without seroconversion to hepatitis B surface antibody (anti-HBs) after completion of a finite course of treatment, was first officially proposed as the goal of new HBV therapies in 2016 AASLD-EASL endpoint workshop and further discussed in 2019 AASLD-EASL endpoint conference. 8,9 Many new drugs aiming for HBV functional cure such as direct-acting antivirals, viral antigen production/release inhibitors, and immunomodulators are in development, many of which are being or have been tested in Phase II clinical trials with some promising readouts. 10 Although the benefits of HBV functional cure have been widely accepted by professionals in hepatology and clinical development of cure regimens are prosperous, patients' awareness and acceptance were barely reported. To better understand CHB patients' medical needs and to support a patient-centric strategy in HBV functional cure drug development, we conducted an internet-based anonymous survey to find out current treatment status, awareness of HBV functional cure and willingness to participate in related clinical trials among CHB patients in China. Patient recruitment, survey questionnaire distribution and data collection were conducted by iGandan, an online platform for liver disease care in China. From October 2022 to February 2023, 80 iGandan-registered doctors fr -Abstract Truncated-
medicine, general & internal